No Data
SINOPHARM (01099.HK) was increased by 2.8236 million shares by CITIC SEC Asset Management.
On December 13, according to the latest equity disclosure information from the Stock Exchange, on December 11, 2024, SINOPHARM (01099.HK) was increased by CITIC SEC Asset Management Co., Ltd. by 2.8236 million shares at an average price of HKD 21.2531 per share, involving an investment of approximately HKD 60.0103 million. After the increase, CITIC SEC Asset Management Co., Ltd.'s latest shareholding is 108,286,000 shares, with the shareholding ratio rising from 7.86% to 8.07%.
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Sinopharm Group Co (OtherSHTDF)
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
Hong Kong stock concept tracking | The biocontrol bill was not included in the latest version of NDAA. Institutions are bullish on the bottom opportunities in the CXO sector (with concept stocks attached).
On December 7, 2024, local time in the USA, the US Congressional Armed Services Committees in both the House and the Senate released the final agreement text of the 2025 National Defense Authorization Act (NDAA), which incorporates proposals from both chambers.
Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.
CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
No Data
Cui Nyonya Kueh :
Musang Siguntang : ???